Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
about
Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a caseOATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells.
P2860
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
@en
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
@nl
type
label
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
@en
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
@nl
prefLabel
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
@en
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
@nl
P2093
P2860
P1476
Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
@en
P2093
P2860
P304
P356
10.1177/030006059902700301
P577
1999-05-01T00:00:00Z